Erenumab – an antimigraine drug: experience of use
- Autores: Azimova Y.E.1,2, Skorobogatykh K.V.1, Osipova V.V.1,3, Korobkova D.Z.1, Mamkhegov E.Z.1, Galanina A.S.1, Guziy E.A.1, Frolova A.V.1
-
Afiliações:
- University Headache Clinic
- Research Institute of General Pathology and Pathophysiology
- Z.P. Solovyov Scientific and Practical Psychoneurological Center of the Moscow Healthcare Department
- Edição: Volume 31, Nº 1 (2024)
- Páginas: 164-168
- Seção: Neurology
- URL: https://journals.eco-vector.com/2073-4034/article/view/632276
- DOI: https://doi.org/10.18565/pharmateca.2024.1.164-168
- ID: 632276
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Background. Studies of the effectiveness and safety of anti-CGRP therapy in routine clinical practice (Real World Studies), where patients with different forms of migraine, varying sensitivity to anti-migraine therapy, as well as concomitant and comorbid diseases are encountered, provide important information for neurologists.
Objective. Evaluation of the effectiveness, safety, and patterns of use of erenumab in the routine practice of a specialized headache center in the Russian Federation.
Methods. The open retrospective study included 126 patients followed-up at the University Headache Clinic (Moscow). The mean age of the patients was 40.3±9–10 years (19–67), women predominated (F – 111, M – 15).
Results. Before treatment, the frequency of days with migraine in the study group was 21.1±7.6 days; after 12 weeks, this figure was 10.2±8.3 (p<0.0001). Among patients with episodic migraine (EM), the frequency of days with migraine before therapy was 11.8±3.7, and after 12 weeks – 4.0 ± 3.3 (p < 0.0001). In the chronic migraine (CM) group, the frequency of days with migraine before treatment was 23.8±6.2, and after 12 weeks it was 11.9 ± 8.5 (p < 0.0001). The proportion of patients with ≥50% reduction in days with migraine after 12 weeks of therapy was 68.3% (n=86), with ≥75% reduction – 32.5% (n=41). The proportion of patients with a complete (100%) reduction in migraine days was 5.6% (n=7). In the EM group, the proportion of patients with ≥50% reduction was 86.2% (n=25), with ≥75% reduction – 41.4% (n=12). In the CM group, the proportion of patients with ≥50% reduction was 62.9% (n=61), with ≥75% reduction – 29.9% (n=41). It should be noted that erenumab was well tolerated at a dose of 70 mg once a month: one patient developed a tendency to constipation, and one patient experienced an increase in blood pressure.
Conclusion. Thus, erenumab is an effective and safe drug for the prevention of migraine in everyday practice and can be recommended for patients with various forms of migraine.
Texto integral
Sobre autores
Yulia Azimova
University Headache Clinic; Research Institute of General Pathology and Pathophysiology
Autor responsável pela correspondência
Email: azimova.j@mail.ru
Dr. Sci. (Med.), neurologist, Leading Researcher at the Laboratory of Fundamental and Applied Problems of Pain
Rússia, Moscow; MoscowK. Skorobogatykh
University Headache Clinic
Email: azimova.j@mail.ru
Rússia, Moscow
V. Osipova
University Headache Clinic; Z.P. Solovyov Scientific and Practical Psychoneurological Center of the Moscow Healthcare Department
Email: azimova.j@mail.ru
Rússia, Moscow; Moscow
D. Korobkova
University Headache Clinic
Email: azimova.j@mail.ru
Rússia, Moscow
E. Mamkhegov
University Headache Clinic
Email: azimova.j@mail.ru
Rússia, Moscow
A. Galanina
University Headache Clinic
Email: azimova.j@mail.ru
Rússia, Moscow
E. Guziy
University Headache Clinic
Email: azimova.j@mail.ru
Rússia, Moscow
A. Frolova
University Headache Clinic
Email: azimova.j@mail.ru
Rússia, Moscow
Bibliografia
- Бельская Г.Н., Кирьянова Е.А., Красников А.В. и др. Результаты оценки эффективности эренумаба в амбулаторной практике невролога. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(7):74–80. Bel’skaya G.N., Kir’yanova E.A., Krasnikov A.V., et al. Results of assessing the effectiveness of erenumab in outpatient neurologist practice. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(7):74–80. (In Russ.)].
- Добрынина Л.А., Губанова М.В., Белопасова А.В. и др. Эффективность и безопасность эренумаба у пациентов с частой эпизодической мигренью по данным российского исследования реальной клинической практики Научного центра неврологии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(2):74–80. [Dobrynina L.A., Gubanova M.V., Belopasova A.V., et al. Efficacy and safety of erenumab in patients with frequent episodic migraine according to a Russian study of real clinical practice of the Scientific Center of Neurology. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(2):74–80. (In Russ.)].
- Екушева Е.В., Артеменко А.Р., Ширшова Е.В. и др. Применение Эренумаба у пациентов с хронической мигренью в реальной клинической практике. Российский неврологический журнал. 2021;26(5):44–50. [Ekusheva E.V., Artemenko A.R., Shirshova E.V., et al. The use of Erenumab in patients with chronic migraine in real clinical practice. Rossiiskii nevrologicheskii zhurnal. 2021;26(5):44–50. (In Russ.)].
- Becker W.J., Spacey S., Leroux E., et al. A real-world, observational study of erenumab for migraine prevention in Canadian patients. Headache. 2022;62(4):522–29. doi: 10.1111/head.14291.
- Cullum C.K., Do T.P., Ashina M., et al. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain. 2022;23(61). doi: 10.1186/s10194-022-01433-9.
- Dodick D.W., Ashina M., Brandes J.L., et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–37. doi: 10.1177/0333102418759786.
- Ferrari M.D., Reuter U., Goadsby P.J., et alTwo-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study. J Neurol Neurosurg Psych. 2022;93:254–62. doi: 10.1136/jnnp-2021-327480.
- Garelja M.L., Alexander T.I., Bennie A., et al. Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors. Br J Pharmacol. 2024;181(1):142–61. doi: 10.1111/bph.16218.
- GBD 2015 Disease and Injury Incidence and Prevlence Collaborators. Global, regional, andnational incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602. doi: 10.1016/S0140-6736(16)31678-6.
- Gladstone J., Chhibber S., Minhas J., et al. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study. Headache. 2022;62(1):78–88. doi: 10.1111/head.14218.
- Goadsby P.J., Reuter U., Hallström Y., et al. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020;95(5):e469–79. doi: 10.1212/WNL.0000000000010019.
- Lanteri-Minet M., Fabre R., Martin C., et al. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study. J Headache Pain. 2023;24(1):152. doi: 10.1186/s10194-023-01680-4.
- Pathak P., Yue L., Gupta S., et al. Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey. Curr Med Res Opin. 2023;39(12):1585–91. doi: 10.1080/03007995.2023.2191479.
- Troy E., Shrukalla A.A., Buture A., et al. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months. J Headache Pain. 2023;24(1):5. doi: 10.1186/s10194-022-01536-3.
- Yu S., Kim B.K., Wang H., et al. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain. 2022;23(1):146. doi: 10.1186/s10194-022-01514-9.
Arquivos suplementares
